Leerink Partnrs Has Positive Outlook for TRVI Q2 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a report issued on Wednesday, June 11th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.39) EPS.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04.

Other research analysts have also issued reports about the company. Wall Street Zen lowered Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital restated a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, June 2nd. B. Riley reaffirmed a "buy" rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Trevi Therapeutics presently has an average rating of "Buy" and an average target price of $20.29.

Trevi Therapeutics Price Performance

Shares of TRVI traded up $0.25 during mid-day trading on Friday, reaching $6.34. The company had a trading volume of 1,231,889 shares, compared to its average volume of 1,357,655. The company has a market capitalization of $743.64 million, a P/E ratio of -14.41 and a beta of 0.59. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $7.48. The company's 50-day moving average is $6.31 and its 200-day moving average is $5.16.

Insider Activity

In other news, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 18.30% of the company's stock.

Institutional Trading of Trevi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. raised its stake in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after buying an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $17,099,000. Vanguard Group Inc. raised its position in shares of Trevi Therapeutics by 9.4% during the 1st quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company's stock valued at $24,141,000 after acquiring an additional 328,819 shares during the last quarter. Vivo Capital LLC lifted its stake in shares of Trevi Therapeutics by 116.3% in the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock valued at $14,370,000 after purchasing an additional 1,875,000 shares during the period. Finally, MPM Bioimpact LLC boosted its position in shares of Trevi Therapeutics by 10.8% in the 1st quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company's stock worth $21,564,000 after purchasing an additional 333,470 shares during the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.